Moderna slides as post-EU-approval rally fades and earnings loom May 1
Moderna shares fell about 3% on April 24, 2026, as the stock gave back gains from this week’s Europe-related regulatory catalyst. The pullback comes with investors positioning ahead of Moderna’s next earnings report expected May 1, 2026.
1. What’s moving the stock today
Moderna (MRNA) traded lower on Friday, April 24, 2026, with the move looking driven by post-catalyst profit-taking after a recent Europe regulatory milestone for its next-generation COVID vaccine brand mNEXSPIKE, alongside positioning ahead of the company’s upcoming quarterly earnings report expected on May 1, 2026. With the stock having run into the event window, incremental buyers appeared to step back, leaving shares vulnerable to routine de-risking and broader risk rotation in U.S. equities.
2. The catalyst investors are fading
In Europe, the European Medicines Agency documentation lists an EU-wide marketing authorization for mNEXSPIKE granted on February 12, 2026, which helped reinforce Moderna’s newer COVID vaccine franchise narrative. But once a regulatory headline is absorbed, the near-term trading focus often shifts back to execution—commercial uptake, pricing, competition, and how fast newer products can offset the structural decline in pandemic-era COVID vaccine demand.
3. Why the timing matters: earnings ahead
The pullback also comes as investors look ahead to Moderna’s next financial update, with market calendars flagging a late-April to early-May reporting window and multiple trackers pointing to a May 1, 2026 report date. Into earnings, sentiment can swing on guidance for 2026 revenue and cash burn, updates on vaccine launches and contracting, and any changes to expected timelines for pipeline programs—making some holders more willing to trim risk after a recent bounce.